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Yacon (Smallanthus sonchifolius), a tuberous root native to the Andean region of South America, contains
high concentration of fructans with potential for colon cancer prevention. This study investigated the
potential beneﬁcial of yacon intake on colon carcinogenesis induced by 1,2-dimethylhydrazine (DMH)
in male Wistar rats. After 4 weeks of DMH-initiation, groups were fed basal diet (G1 and G6) or basal diet
containing dried extract of yacon root at 0.5% (G2), 1.0% (G3 and G5) or a synbiotic formulation (G4) (1.0%
yacon plus Lactobacillus casei at 2.5  1010 CFU per g diet) for 13 weeks. At week 20, a signiﬁcant reduc-
tion in number and multiplicity of aberrant crypt foci (ACF) and in number of invasive adenocarcinomas
was observed in the groups orally treated with 1.0% yacon (G3) or the synbiotic formulation (G4)
(0.05 < p < 0.001). Tumor multiplicity (noninvasive plus invasive) was signiﬁcantly lower in the group
fed synbiotic formulation (p < 0.02). A signiﬁcant reduction in cell proliferation in colonic crypts and
tumors and short chain fatty acids (SCFA) caecal contents was observed in the groups orally treated with
1.0% yacon (G3) or the synbiotic formulation (G4). Therefore, the ﬁndings this study indicate that yacon
and yacon plus L. casei intake may reduce the development of chemically-induced colon cancer.
 2012 Elsevier Ltd. Open access under the Elsevier OA license.1. Introduction
Colon cancer is a signiﬁcant cause of mortality from cancer
among men and woman in industrialized Western societies (Jemal
et al., 2011). Although its etiology is multifactorial and complex, it
is generally accepted that the hereditary genetic component asso-
ciated with dietary habits such as low intake of ﬁbers, proteins,
fruits and vegetables as well as diets with high red and processed
meat and fat levels are among the greatest risk factors (Khan et al.,
2010; van Engeland et al., 2011; Bastide et al., 2011; Watson and
Collins, 2011). Compelling laboratory animal and epidemiologic
evidences indicate that lifestyle and dietary habits have been asso-
ciated with up- or down-regulation of the risk for colon cancer on-
set and progression (Erdelyi et al., 2009; van Engeland et al., 2011).
Recently, there are great scientiﬁc and public interest in studies of
colon cancer chemoprevention for identiﬁcation of naturally occur-
ring substances present in food (Tarapore et al., 2012; Poulsende Morfologia, Instituto de
), Botucatu 18618-970, SP,
an).
lsevier OA license.et al., 2011). Chemically-induced models of colon carcinogenesis
in rodents have been suitable for the study of risk factors, preven-
tion and tumor development (Raju, 2008; Namasivayam, 2011).
Colon cancer has been postulated as a complex and multistage
process well established in both humans and experimental models
(Takahashi and Wakabayashi, 2004; Tanaka, 2009). The stages of
colon carcinogenesis are accompanied by several biochemical, mor-
phological, genetic, and epigenetic alterations in the colonic muco-
sa (Takahashi andWakabayashi, 2004). Development of rodent and
human colon cancer includes a series of pathological alterations
ranging from discrete microscopic mucosal lesions like aberrant
crypt foci (ACF) to malignant tumors (Gupta and Schoen, 2009;
Tanaka, 2009). ACF are considered putative preneoplastic lesions
since they are found in the colonic mucosa of rodents treated with
chemical carcinogens (Bird and Good, 2000; Cheng and Lai, 2003)
and in patients at high risk for development of colon cancer (Khare
et al., 2009). ACF can be easily induced in rodent colon after single
or multiple administrations of 1,2-dimethylhydrazine (DMH) or its
metabolite azoxymethane (Tanaka, 2009). ACF detection and quan-
tiﬁcation have been proposed for identiﬁcation of potential chemo-
preventive agents in rodent short- and medium-term bioassays of
colon carcinogenesis (Bird and Good, 2000; Raju, 2008).
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designated as b-catenin-accumulated crypts (BCAC) or surrogate
premalignant lesions, and seem to progress more likely colon can-
cer as compared to classical ACF (Yoshimi et al., 2004; Mori et al.,
2005; Suehiro and Hinoda, 2008). b-catenin is a structural protein
encoded by CTNNB1 gene, that acts as a component of the cad-
herin-mediated cell-cell adhesion complex and as a transcriptional
activator mediating Wnt signal transduction of immediate gene
targets (Barker and Clevers, 2007). Free b-catenin in the cytoplasm
binds to the glycogen synthase kinase-3 (GSK-3b)-axin-adenoma-
tous polyposis coli (APC) protein complex and it is phosphorylated
by GSK-3b occurring their proteosome-mediated degradation (26S
proteosome) (Barker and Clevers, 2007). Nuclear b-catenin acti-
vated transcription factors such as T-cell factor/lymphoid enhan-
cer-binding factor (TCF/LEF) where it serves as a transcription
regulator for several genes that regulate tumor progression and
invasion. b-catenin aberrant expression is frequently detected in
chemically-induced colon tumors in rats and mice (Ochiai et al.,
2003; Hata et al., 2004; Takahashi and Wakabayashi, 2004) and
in human colon cancer (Hao et al., 2001) suggesting that altera-
tions of b-catenin may be early events in rodent and human colo-
rectal carcinogenesis.
Yacon (Smallanthus sonchifolius Poepp. and Endl., Asteraceae) is a
perennial plant originally native of Andean region of South America
(Zardini, 1991; Valentová et al., 2006). There are reports on yacon
cultivation in other countries, including EUA, Europe, New Zealand
and Brazil (Valentová et al., 2006). Yacon has been cultivated in
south-eastern Brazil as a crop since 1991 yielding up to 100 t/ha
(Vilhena et al., 2000). In folk medicine, yacon tuberous roots and
infusions from dried leaves are consumed by people suffering from
diabetes or from various digestive or renal disorders (Valentová
et al., 2006). Its tuberous roots are consumed fresh or cooked and
it has been considered a functional food because of the large
amounts of fructans (i.e., inulin and fructooligosaccharides) (Valen-
tová et al., 2006). Fructans are carbohydrates reserve which con-
tains up to 70 fructose units linked or not to a terminal sucrose
molecule, may have linear or branched structure held together by
frutosil-fructose bonds (Roberfroid and Delzenne, 1998; Pedreschi
et al., 2003). Studies have shown that the best period to harvest ya-
con in tropical regions is between the 31st and 35th week after cul-
tivation, regarding the concentration of fructans and their
proportion in relation to mono- and disaccharides (Oliveira and
Nishimoto, 2004). The yacon plants present a high hydrolytic activ-
ity at maturation phase of the tuberous roots, contributing to the
predominance of a low degree of polymerization such as fructooli-
gosaccharides (FOS, DP < 10) rather than fermentable long-term
fraction fructans (DP > 10) (Itaya et al., 2002; Lobo et al., 2007).
A prebiotic, as deﬁned by Gibson and Roberfroid (1995), is ‘‘a
nondigestible food ingredient that beneﬁcially affects the host by
selectively stimulating the growth and activity of one or a limited
number of bacteria in the colon with the potential to improve host
health. A number of poorly digested carbohydrates fall into the cat-
egory of prebiotics, including certain ﬁbers and resistant starches,
but the most widely described prebiotics are non-digestible oligo-
saccharides. Combinations of probiotics and prebiotics can result
in additive or synergistic effects on gastrointestinal function
(Pool-Zobel and Sauer, 2007; Fotiadis et al., 2008). FOS are prospec-
tive prebiotics as they are fermented by beneﬁcial species of gut
bacteria (Gibson and Roberfroid, 1995; Havenaar, 2011; DuPont
and DuPont, 2011). They are also used as a source of natural sweet-
eners and syrups suitable for persons suffering from digestive
problems (Charalampopoulos and Rastall, 2012). Oral treatment
with yacon syrup markedly accelerated colonic transit time in
healthy individuals (Geyer et al., 2008) and increased defecation
frequency and satiety sensation in obese and slightly dyslipidemic
pre-menopausal women (Genta et al., 2009).Considering the large amounts of fructooligosaccharides de-
tected in yacon tuberous roots and its increased popularity and
consumption, the present study aimed to investigate the potential
chemopreventive action of 0.5% and 1.0% dried extract of yacon
root intake on the ACF and tumor development in the rat colon car-
cinogenesis induced by DMH. In addition, the beneﬁcial effects of
yacon root in association with Lactobacillus casei (i.e., a synbiotic
formulation) were also evaluated.2. Material and methods
2.1. Animals and treatment
The animals used in this study were handled in accordance with the Ethical
Principles for Animals Research adopted by the Brazilian College of Animal Exper-
imentation (COBEA). The experimental protocol used herein was approved by the
local University Ethics Committee for Animal Research.
Four-week-old male Wistar rats were obtained from Centro de Tecnologia do
Paraná (TECPAR, Araucária PR, Brazil). The animals were housed in polypropylene
cages covered with metallic grids in a room maintained at 22 ± 2 C, 55 ± 10%
humidity under a 12-h light–dark cycle. After a 2-week acclimation period to the
housing environment, the animals were randomly distributed into six groups (5
or 12 rats each): Groups 1 to 4 were treated with four subcutaneous injections of
40 mg/kg body weight 1,2-dimethylhydrazine hydrochloride (DMH, Sigma–Aldrich,
Co, USA) (Dias et al., 2006, 2010), twice a week for 2 weeks. Groups 5 and 6 received
similar injections of EDTA solution at pH 6.0 (DMH vehicle). After 4 weeks of DMH-
initiation,G1 and G6 groups were fed basal diet (Nuvilab-CR-1, Curitiba-PR, Brazil)
and G2, G3, G4 and G5 groups received basal diet containing dried extract of yacon
root at 0.5%, 1.0%, a synbiotic formulation (dried extract of yacon root at 1.0% plus
Lactobacillus casei at 2.5  1010 de CFU per g diet) or dried extract of yacon root at
1.0%, respectively, for 13 weeks (week 7–20). At the end of the week 20, the animals
were killed by exsanguination under sodium pentobarbital anesthesia (45 mg/kg
body weight). Individual body weight and food consumption were recorded twice
a week during the experimental period.
2.2. Preparation of dried extract of yacon root, synbiotic formulation and determination
of fructans
The probiotic Lactobacillus casei (lyophilized power containing 2  1010 live
cells/g, Future Ceuticals, USA, Lot. 90715LC10N4710) was incorporated into basal
diet at 2.5  1010 de CFU per g diet. The yacon roots were washed, cut into
1.5 cm thick cubes and heated for 10 min at 90 C in water under slowly stirring.
Then, cubes were grounded and its pulp was sieved (150 mesh) and heated for
10 min at 90 C under slowly stirring. Samples of dried extract of yacon root were
obtained by spray dryer process using maltodextrin as a carrier agent. The spray
drying process was performed in a laboratory scale spray dryer with a 0.2 mm
diameter nozzle (R.A.B Ranazzi and Co. Ltd., Brazil). The feed ﬂow rate used was
25 ml/min and the inlet and outlet air temperatures were 230–250 C and 100–
110 C, respectively. A synbiotic formulation was produced by dietary association
between yacon root at 1.0% plus Lactobacillus casei.
The fructooligosaccharides (FOS) was analyzed by high performing liquid chro-
matography (HPLC) using ProStar Varian model (Hubbardston, MA, USA). The sug-
ars separation was achieved on a Biorad Aminex HPX-87P model column and RI350
detector. Mobile phase consisted of deionized water and detection of maltodextrin,
FOS, sucrose, glucose and fructose (12.120, 13.307, and 19.608, 24.425 and 37.926
retention time) was performed at ﬂow rate of 0.8 mL/min. The concentrations of
maltodextrin, FOS, sucrose, glucose and fructose were calculated from standard
curves prepared with puriﬁed standards (Sigma–Aldrich, Co, USA). The chemical
analysis revealed that dried extract of yacon root used in this study contained
20.4% FOS 4.8% sucrose, 2.8% glucose, 6.8% fructose and 16.7% maltodextrin. Equiv-
alent quantities from sucrose, glucose, fructose and maltodextrin were added into
basal diet from G1 and G6 groups. Thus, control diet and diet containing dried ex-
tract of yacon root at 1.0% were formulated in order to provide similar caloric
energy.
2.3. Colon processing and histopathological analysis
At necropsy, caecal content was collected on ice into a vial, and frozen at 80 C
for short chain fatty acids (SCFA) analyses The colon was removed, opened longitu-
dinally and gently rinsed with saline to remove residual bowel contents and, then,
ﬁxed ﬂat in 10% buffered formalin for 24 h at room temperature. The localization
and volume of each tumor were registered. Then middle and distal colon were
stained with 1.0% methylene blue dissolved in phosphate-buffered salt solution
(PBS) for analysis and quantiﬁcation of classical ACF (Dias et al., 2006, 2010). ACF
were identiﬁed according to Bird criteria (Bird and Good, 2000). The number of
ACF/colon, number of aberrant crypts in each ACF (multiplicity)/colon and the num-
ber of ACF with 1–3, 4–9 or >9 aberrant crypts (AC)/colon were determined under
0
10
20
30
40
50
60
70
80
90
100
1 3 5 7 9 11 13 15 17 19 20
Weeks
Su
rv
iv
al
 (%
)
G1
G2
G3
G4
G5
G6
A
Groups 
0
5
10
15
20
25
G1 G2 G3 G4
Large (> 0.60 cm3)
Medium (0.30-0.60 cm3)
Small (< 0.30 cm3)
B
Groups 
Tu
m
o
r 
pe
rc
en
ta
ge
 (%
)
Fig. 1. (A) Kaplan–Meier analysis of animal survival in the different groups during
experiment. (B) Data from tumor size (cm3) in the colon of DMH-treated animals.
G1 = DMH-initiated and fed basal diet, G2 = DMH-initiated and fed basal diet
containing 0.5% yacon, G3 = DMH-initiated and fed basal diet containing 1.0%
yacon; G4 = DMH-initiated and fed basal diet containing synbiotic formulation (L.
casei at 2.5  1010 CFU/kg basal diet plus 1.0% yacon), G5 = Vehicle-treated and fed
basal diet containing 1.0% yacon, G6 = Untreated. DMH = 1,2 dimethylhydrazine
dihydrochloride (4  40 mg/kg b.wt., s.c.).
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Swiss-rolled (4–6, 2-mm width segments) and embedded in parafﬁn. Histological
evaluation was carried out on hematoxylin-eosin (HE)-stained colon sections and
ACF were classiﬁed as conventional or dysplastic lesions, according to Yoshimi
et al. (2004). Colon tumors were classiﬁed as adenomas or adenocarcinomas,
according to Hamilton and Aaltonen (2000). In addition, the colonic adenocarcino-
mas were classiﬁed into invasive and non-invasive type (i.e., based on invasion into
submucosa and muscularis) and their incidence (% rats with tumor), and multiplic-
ity (number of tumor/rat) were also calculated.
2.4. Immunohistochemical procedures
Proliferating cell nuclear antigen (PCNA), cleaved caspase-3 and b-catenin
expression in colon sections were immunohistochemically detected using a poly-
mer system (MACH 4 Universal HRP polymer Detection, Biocare, CA, USA). Brieﬂy,
deparafﬁnated 5-lm colon sections on silanized slides were treated sequentially
with 0.01 M citrate buffer (pH 6.0) at 120 C for 5 min in a Pascal Pressure Chamber
(Dako Cytomation Denmark A/S), 3% H2O2 in phosphate-buffered saline (PBS) for
10 min, nonfat milk for 60 min, mouse anti-PCNA (clone PC10, 1:200 dilution,
DakoCytomation Denmark A/S, Glostrup, Denmark), rabbit polyclonal cleaved
anti-caspase-3 (clone Asp 175, 1:100 dilution, Cell Signalizing Technology, Inc.,
Danvers, MA, USA) or anti-b-catenin (clone ab16051, Abcam, MA, USA) antibodies
overnight at 4 C, mouse probe and HRP polymer for 30 min each at room temper-
ature. Chromogen color development was accomplished with 3,30-diaminobenzi-
dine tetrahydrochroride (Sigma–Aldrich, Co, USA). The slides were counterstained
with Harris hematoxylin.
2.5. PCNA, cleaved caspase-3 and b-catenin analysis
At least 20 perpendicular well-oriented normal-appearing crypts from the mid-
dle and distal colon were examined in each animal (groups G1–G6) under light
microscopy The index of colonic crypt cells expressing proliferating cell nuclear
antigen (PCNA) or cleaved caspase-3 was evaluated as the percentage among the to-
tal number of cells analyzed in a perpendicular colonic crypt. Also, PCNA and
cleaved caspase-3 indexes (500 cells) and b-catenin expression were assessed in
colon tumors. The abnormal expression of b-catenin (i.e., cytoplasm and nucleus)
was evaluated in each colon tumor according to Yoshimi et al. (2004) and Femia
et al. (2004).
2.6. Determination of caecal short chain fatty acids (SCFA)
The amount of SCFA in caecal contents was analyzed by gas chromatograph
detection according to the methodology described by Zhao et al. (2006). Quantiﬁca-
tion of acetic, propionic, butyric, acid was carried out by comparing peak areas to
those of pure standards of known concentration. Acetic acid, 100%, propionic acid,
99%, butyric acid, 99.5% were used by external calibration standard curves.
2.7. Statistical analysis
The statistical analysis was performed using the Jandel Sigma Stat software
(Jandel Corporation, San Rafael, CA, USA). Data from body weight gain, food con-
sumption, ACF and tumor number and multiplicity/colon, cell proliferation and
apoptosis indexes and SCFA were compared among the groups. Besides, incidence
of conventional and dysplastic ACF, colon tumor and altered b-catenin expression
were compared by chi-square or the Fischer exact tests. The differences among
groups were considered signiﬁcant when p < 0.05.
3. Results
3.1. General ﬁndings
The mean body weights of respective DMH- and vehicle-treated
groups fed yacon or the synbiotic formulation did not differ from
the groups receiving basal diet (data not showed). Among DMH-
initiated groups (G1–G4), the survival rate was higher in the group
orally receiving synbiotic formulation (G4) when compared to the
group fed basal diet (G1) (Fig. 1A), although without signiﬁcant dif-
ference. Oral treatment throughout 13 weeks (week 7–20) with ya-
con or the synbiotic formulation did not change body-weight gain
or food consumption (Table 1). At sacriﬁce (week 20), serum glu-
cose, triglycerides and total cholesterol levels were similar among
the different groups, but the relative liver weight was signiﬁcantly
lower (p = 0.04) in the group receiving synbiotic formulation (G4)
than in the DMH-treated group fed basal diet (G1) (Table 1). The
mean daily intake estimated of FOS was approximately 73.90,150.74, 147.65 and 123.26 mg/kg of body weight for G2, G3, G4
and G5 groups, respectively.
Speciﬁc SCFA concentrations (lmol/g) of caecal content in
DMH-initiated groups are shown in Fig. 2. Acetic and butyric acid
content were signiﬁcantly higher (0.01 < p < 0.001) in the groups
fed 1.0% yacon (G3) or the synbiotic formulation (G4) than in the
group fed basal diet (G1). Caecal propionate concentrations were
not signiﬁcantly modiﬁed by the different treatments.
3.2. Classical ACF analyses
Classical ACF were evaluated in methylene blue-stained whole
mount colon at the end of week 20 (Fig. 3A and B). Data from
the number and multiplicity of stereoscopically-analyzed ACF in
the different groups are summarized in Table 2. All DMH-initiated
animals developed classical ACF in the colon (G1–G4) while no pre-
neoplastic lesion was detected in the colon from vehicle-treated
groups (G5 and G6).
The total number of aberrant crypts AC and ACF and multiplic-
ity (AC/ACF) were signiﬁcantly lower (p = 0.013, p < 0.05 and
p = 0.003, respectively) in the groups orally treated with 1.0% yacon
(G3) or the synbiotic formulation (G4) when compared to the
group fed basal diet (G1). The number of ACF containing 4–9 crypts
(Fig. 3A) was signiﬁcantly lower (p = 0.018) in the group receiving
1.0% dried root yacon (G3) and the synbiotic formulation (G4)
when compared to the respective control group (G1). Also, the
number of ACF containing more than 9 crypts (Fig. 3B) was signif-
icantly lower (p = 0.001) in groups fed 0.5% and 1.0% yacon (G2 and
Table 1
Effects of dietary yacon on general data, relative weight organs and biochemical parameters in different groupsa.
Parameters Group/treatmentb
DMH-initiated Non-initiated
(G1) Untreated
12/08c
(G2) Yacon 0.5%
12/08
(G3) Yacon 1.0%
12/10
(G4) Syn
12/12
(G5) 1.0% yacon
05/05
(G6) Untreated
05/05
General data
Final body weight (g) 388.0 ± 18.27 401.37 ± 10.55 401.70 ± 11.02 422.0 ± 12.70 479.0 ± 13.25⁄ 452.6 ± 13.84
Body-weight gain (g) 78.0 ± 17.04 99.29 ± 10.70 95.22 ± 16.50 91.92 ± 7.72 104.80 ± 6.35 79.40 ± 2.31
Food consumption (g/rat/day)4 25.53 ± 0.61 23.62 ± 0.83 23.89 ± 0.84 24.37 ± 0.71 23.22 ± 0.76 24.52 ± 1.14
Yacon consumption (mg/rat/day) 0 125.16 ± 4.06 252.97 ± 8.09 254.86 ± 7.44 243.05 ± 8.97 0
Relative weight organs (%)
Liver 2.86 ± 0.17 2.42 ± 0.10 2.56 ± 0.11 2.37 ± 0.11⁄ 2.42 ± 0.12 2.59 ± 0.12
Right kidney 0.29 ± 0.01 0.27 ± 0.01 0.27 ± 0.02 0.27 ± 0.02 0.25 ± 0.01 0.27 ± 0.01
Left kidney 0.29 ± 0.02 0.26 ± 0.01 0.27 ± 0.01 0.26 ± 0.01 0.26 ± 0.01 0.26 ± 0.01
Biochemical data
Glucose (mg/dL) 111.85 ± 7.84 104.06 ± 11.35 106.72 ± 4.91 102.01 ± 7.55 112.94 ± 7.04 114.60 ± 17.21
Triglycerides (mg/dL) 68.94 ± 3.32 60.10 ± 5.18 66.54 ± 6.19 66.10 ± 4.77 69.80 ± 6.07 62.50 ± 6.49
Cholesterol (mg/dL) 68.00 ± 2.86 64.33 ± 2.98 64.28 ± 3.27 61.87 ± 1.94 74.79 ± 2.73 78.18 ± 5.28
a Values are mean ± SE.
b DMH = 1,2 dimethylhydrazine dihydrochloride (4  40 mg/kg b.wt., s.c.); yacon = 0.5% or 1.0% dried extract of yacon root in the basal diet for 13 weeks; Syn = synbiotic (L.
casei at 2.5  1010 CFU/kg basal diet plus 1.0% yacon).
c Number of animals: initial/ﬁnal.
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Fig. 2. SCFA concentration in caecal contents in DMH-initiated groups (n = 8).
G1 = Fed basal diet, G2 = Fed basal diet containing 0.5% yacon, G3 = Fed basal diet
containing 1.0% yacon; G4 = Fed basal diet containing synbiotic formulation (L. casei
at 2.5  1010 CFU/kg basal diet plus 1.0% yacon). G1 = DMH-initiated and fed basal
diet, G2 = DMH-initiated and fed basal diet containing 0.5% yacon, G3 = DMH-
initiated and fed basal diet containing 1.0% yacon; G4 = DMH-initiated and fed basal
diet containing synbiotic formulation (L. casei at 2.5  1010 CFU/kg basal diet plus
1.0% yacon). DMH = 1,2 dimethylhydrazine dihydrochloride (4  40 mg/kg b.wt.,
s.c.). ⁄Different from G1 group, 0.01 < p < 0.001.
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respective control group fed basal diet (G1).3.3. Tumor size and multiplicity and histopathology analyses
At sacriﬁce, all macroscopic tumors were measured and classi-
ﬁed into three categories: small (<0.30 cm3), medium (0.30–
0.60 cm3) and large (>0.60 cm3) (Fig. 1B). A reduction in the mean
tumor size (cm3) was observed in groups orally receiving 0,5% and
1.0% yacon (G2 and G3) or the synbiotic formulation (G4) when
compared to the group fed basal diet (G1) (Table 3), although with-
out a signiﬁcant difference.
Nondysplastic ACF (Fig. 3C) were observed in all DMH-treated
groups (G1–G4), but a few number of animals presented dysplastic
ACF (Fig. 3D). A signiﬁcant reduction (p < 0.05) in incidence of
dysplastic ACF was observed in groups fed 1.0% yacon (G3) or thesynbiotic formulation (G4) when compared to the respective con-
trol group fed basal diet (G1) (Table 3). In general, dyplastic ACF
showed altered b-catenin-accumulated crypts (Fig. 3E). The histo-
pathological analysis by HE-staining revealed that more than 95%
of colon tumors were invasive adenocarcinomas and less than 5%
the remaining were in situ adenocarcinomas.
The mean number of invasive adenocarcinomas were signiﬁ-
cantly lower (p = 0.02) in the groups fed 1.0% yacon (G3) or the
synbiotic formulation (G4). A signiﬁcant reduction (p = 0.02) in tu-
mor multiplicity (noninvasive and invasive tumor) was observed in
the group fed synbiotic formulation (G4) (Table 3). No tumors were
identiﬁed macroscopically or by histology in the non-initiated
groups fed basal diet (G6) or fed 1.0% yacon (G5).3.4. Cell proliferation, apoptosis and b-catenin analyses
Cell proliferation (PCNA-positive epithelial cells, Fig. 4) and
apoptosis (cleaved caspase-3-positive epithelial cells, Fig. 5) in-
dexes were analyzed in the ‘‘normal-appearing’’ crypts and in co-
lon tumors. The proportion of PCNA and cleaved caspase-3
immunoreactivity was markedly and signiﬁcantly higher
(p < 0.001) in colon tumors than in ‘‘normal-appearing’’ colonic
crypts (Figs. 4C and 5C). Also, a signiﬁcant reduction (p < 0.001,
p = 0.039, respectively) in the cell proliferation indexes was ob-
served in the groups fed 1.0% yacon (G3 and G5) or the synbiotic
formulation (G4) when compared to the respective control groups
(G1 and G6) for both ‘‘normal-appearing’’ colonic crypts or colon
tumors analyses (Fig. 4A1–A6, B1–B4 and C). The apoptosis index
was not modiﬁed by dietary yacon (G2 and G3) or the synbiotic
formulation (G4) when compared to the respective control groups
fed basal diet (G1 and G6) (Fig. 5C).
Altered b-catenin expression was analyzed in colon tumors and
compared to the ‘‘normal-appearing’’ crypts showing only mem-
brane b-catenin expression. All adenocarcinomas expressed altered
b-catenin in the cytosol and somemalignant tumors also presented
nuclear positivity for b-catenin (Fig. 3F). A signiﬁcant reduction
(40% and 50%, p < 0.001) in the incidence of colon tumors showing
lower levels of altered b-catenin expression was observed in the
groups fed 1.0% yacon (G3) or the synbiotic formulation (G4),
respectively (Fig. 3G and H) when compared to the respective con-
trol group fed basal diet (G1). (Fig. 3F).
Fig. 3. (A–B) Representative topographic view of classical ACF in a methylene blue-stained colon whole mount containing eight and fourteen aberrant crypts, respectively
(20 objective). (C–D) Representative nondysplastic and dysplastic ACF detected in HE-stained Swiss-rolling sections, respectively (arrows 20 objective). (E) Dysplastic ACF
showing altered b-catenin expression in the cytoplasm and nucleus (40 objective). (F–H) Colon tumors showing altered b-catenin expression in both cytoplasm and nucleus
(strong expression), and mainly in cytoplasm (weak expression) from the groups G1, G3 and G4, respectively (40 objective). ⁄Membrane b-catenin expression in a ‘‘normal-
appearing’’ crypts.
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Prebiotics, probiotics or their combination (synbiotics) have
also been associated to the reduction of experimental colon carci-
nogenesis (Pool-Zobel, 2005; Fotiadis et al., 2008). Fructans present
in foods such as garlic, onion, artichoke, asparagus and yacon have
been demonstrated to increase the levels of probiotics and short
chain fatty acids (SCFA) concentrations in intestinal contents
(Valentová et al., 2006; Pool-Zobel, 2005; Pool-Zobel and Sauer,
2007; Fotiadis et al., 2008). Thus, the present study evaluated the
potential protective effects of the ingestion of yacon root or a syn-
biotic formulation. Thus, the present study evaluated the potential
protective effects of yacon root or a synbiotic formulation (i.e.,potential addictive effect) against chemically-induced colon carci-
nogenesis in male Wistar rats.
A signiﬁcant reduction in development of the classical and dys-
plastic ACF and in the number of invasive colon tumors was ob-
served in the groups fed 1.0% yacon root. These protective effects
of dietary yacon containing high FOS concentrations were associ-
ated to a signiﬁcant increase of SCFA concentrations and a reduc-
tion in the cell proliferation and incidence of colon tumors
expressing altered b-catenin. These ﬁndings are in agreement with
previous observations indicating that prebiotics may reduce the
incidence and multiplicity of chemically-induced colon tumors
(Pool-Zobel, 2005; Pool-Zobel and Sauer, 2007; Fotiadis et al.,
2008).
Table 2
Effects of dietary yacon on development of colonic aberrant crypt foci (ACF) a.
Group/treatmentb Number of ratsc Number of ACF Total number
1–3 crypt 4–9 crypts >9 crypts ACd ACF AC/ACF
DMH-initiated
(G1) Untreated 12/8 30.78 ± 4.79 15.33 ± 4.47 1.89 ± 0.48 304.26 ± 51.27 91.63 ± 11.58 3.25 ± 0.31
(G2) 0.5% yacon 12/8 23.62 ± 5.60 6.37 ± 1.53 0.25 ± 0.25* 153.82 ± 32.44 62.73 ± 11.85 2.40 ± 0.33
(G3) 1.0% yacon 12/10 22.60 ± 5.90 4.10 ± 1.00* 0.30 ± 0.15* 110.04 ± 19.41* 52.82 ± 12.10* 2.19 ± 0.24*
(G4) Syn 12/12 16.08 ± 2.90 3.17 ± 0.90* 0.33 ± 0.26* 103.04 ± 22.08* 51.11 ± 10.03* 1.79 ± 0.20*,**
Non-initiated
(G5) 1.0% yacon 5/5 0 0 0 0 0 0
(G6) Untreated 5/5 0 0 0 0 0 0
a Values are mean ± SE;
b DMH = 1,2 dimethylhydrazine dihydrochloride (4  40 mg/kg b.wt., s.c.); Yacon = 0.5% and 1.0% dried extract of yacon root in the basal diet for 14 weeks; Syn = synbiotic
(L. casei at 2.5  1010 CFU/kg basal diet plus 1% yacon);
c Number of animals: Initial/Final.
d AC = aberrant crypt.
*,** Different from G1 group and G1 and G2 groups, respectively, 0.05 < p < 0.001.
Table 3
Effects of dietary yacon on development of dysplastic ACF (incidence) and colon tumors (incidence and multiplicity).
Group/treatmenta Number of ratsb Displastic ACFc (%) Tumor (%) Multiplicityd Tumor volumed (cm3)
Invasive Non-invasive Total
DMH-initiated
(G1) Untreated 12/8 8 (100) 7 (70) 4.1 ± 1.2 1.5 ± 0.5 5.0 ± 1.4 (38)e 0.61 ± 0.14
(G2) 0.5% yacon 12/8 5 (63) 8 (100) 2.2 ± 0.6 1.5 ± 0.3 3.4 ± 0.4 (27) 0.27 ± 0.06
(G3) 1.0% yacon 12/11 5 (45)* 7 (64) 1.3 ± 0.7* 0.8 ± 0.6 2.9 ± 1.3 (20) 0.32 ± 0.12
(G4) Syn 12/12 3 (25)* 9 (75) 1.2 ± 0.2* 0.7 ± 0.3 1.4 ± 0.2*(16) 0.22 ± 0.10
Non-initiated
(G5) 1.0% yacon 5/5 0 0 0 0 0 0
(G6) Untreated 5/5 0 0 0 0 0 0
a DMH = 1,2 dimethylhydrazine dihydrochloride (4  40 mg/kg b.wt., s.c.); yacon = 0.5% and 1.0% dried extract of root yacon in the basal diet for 14 weeks; Syn = synbiotic
(L. casei at 2.5  1010 CFU/kg basal diet plus 1% yacon).
b Number of animals: initial/ﬁnal.
c ACF = aberrant crypt foci.
d Values are mean ± SE.
e Total number of colon tumors.
*,** Different from G1 group and G1 and G2 groups, respectively, 0.02 < p < 0.001.
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evident toxic effects in experimental and human studies (Genta
et al., 2009; Valentová et al., 2006; Geyer et al., 2008). In an inter-
vention study in obese and dyslipidemic pre-menopausal women,
the recommended and safety daily consumption of yacon syrup
was 0.14 g fructooligosaccharides/kg (Genta et al., 2009). In other
human intervention study, the intake of yacon tubers capsules at
daily dose of 2.4 g was safety and well tolerated in people suffering
from or at risk of metabolic syndrome (Valentová et al., 2006).
However, yacon syrup intake at daily dose of 20 g (equal to 6.4 g
fructooligosaccharides) induced a marked acceleration of colonic
transit time in healthy volunteers included in a placebo-controlled
crossover study (Geyer et al., 2008). The results of present study
indicate that daily dose of FOS in the 1.0% yacon root intake was
150 mg/kg b.w. (0.15 g/kg). This dose did not cause deleterious
effects on the gastrointestinal system of male Wistar rats and it
was a safe dose similar to the recommended for humans (Genta
et al., 2009).
Various studies indicate that gut ﬂora fermentation products of
FOS beneﬁcially modulate tumor progression markers in human
and rat colon tumor cells (Pool-Zobel, 2005; Pool-Zobel and Sauer,
2007; Fotiadis et al., 2008). In the present study, acetate and buty-
rate contents in the caecum were signiﬁcantly increased in DMH-
initiated groups fed 1.0% yacon. In special, butyrate is a protective
agent against colon cancer by promoting cell differentiation, cell-
cycle arrest and apoptosis of transformed colonic epithelial cells;inhibiting the enzyme histone deacetylase and decreasing the
transformation of primary to secondary bile acids as a result of co-
lonic acidiﬁcation (feces) (Wong et al., 2006; Pool-Zobel and Sauer,
2007). Although yacon fructooligosaccharides contain low degree
of polymerization (Ohyama et al., 1990), a signiﬁcant increase in
SCFA production was observed as well as to inulin and Synergy
(high degree of polymerization) that are more slowly fermented
in the large bowel (Roberfroid, 2007). Thus, the protective effects
against colon carcinogenesis by dietary yacon could involve an in-
crease in SCFA production associated to the reduction of develop-
ment of ACF and colon tumor.
The present study evaluated the modifying effects of yacon in-
take on cell proliferation and apoptosis in both ‘‘normal appearing’’
crypts and colonic tumors. Cell proliferation may lead to an in-
creased risk of developing cancer whereas apoptosis is a protective
innate mechanism taking to elimination of the epithelial cells with
DNA damage or genomic instability (Hanahan and Weinberg,
2011). Increase in both cell proliferation and apoptosis indexes
has been documented during development of colon tumors
(Mełen´-Mucha and Niewiadomska, 2002), as also observed in this
present study by differences in levels of cell proliferation/apoptosis
between ‘‘normal appearing’’ crypts and tumor epithelial cells. In
fact, some studies have described an increase in apoptosis levels
in the colon by prebiotics or synbiotic interventions shortly after
carcinogen treatment (Hughes and Rowland, 2001; Le Leu et al.,
2005) rather than in late stages of carcinogenesis (Femia et al.,
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Fig. 4. (A1–A6) Representative ‘‘normal-appearing’’ crypts immunoreactivity for
PCNA (dark nuclei) from the groups G1, G2, G3, G4, G5 and G6, respectively (40
objective). (B1–B4) Representative tumor immunoreactivity for PCNA (dark nuclei)
from the groups G1, G2, G3 and G4, respectively (40 objective). (C) PCNA labeling
indexes for ‘‘normal-appearing’’ crypts and colon tumors in the different groups.
G1 = DMH-initiated and fed basal diet, G2 = DMH-initiated and fed basal diet
containing 0.5% yacon, G3 = DMH-initiated and fed basal diet containing 1.0%
yacon; G4 = DMH-initiated and fed basal diet containing synbiotic formulation (L.
casei at 2.5  1010 CFU/kg basal diet plus 1.0% yacon), G5 = Vehicle-treated and fed
basal diet containing 1.0% yacon, G6 = Vehicle-treated and fed basal diet. DMH = 1,2
dimethylhydrazine dihydrochloride (4  40 mg/kg b.wt., s.c.). ⁄Different from G1
group, p < 0.001.
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Fig. 5. (A–B) Representative ‘‘normal-appearing’’ crypts and tumor immunoreac-
tivity for cleaved caspase-3 (arrows, 40 objective), respectively. (C) Cleaved
caspase-3 labeling indexes for ‘‘normal-appearing’’ crypts and colon tumors in the
different groups. G1 = DMH-initiated and fed basal diet, G2 = DMH-initiated and fed
basal diet containing 0.5% yacon, G3 = DMH-initiated and fed basal diet containing
1.0% yacon; G4 = DMH-initiated and fed basal diet containing synbiotic formulation
(L. casei at 2.5  1010 CFU/kg basal diet plus 1.0% yacon), G5 = Vehicle-treated and
fed basal diet containing 1.0% yacon, G6 = Untreated. DMH = 1,2 dimethylhydrazine
dihydrochloride (4  40 mg/kg b.wt., s.c.).
2908 N.A. de Moura et al. / Food and Chemical Toxicology 50 (2012) 2902–29102002; Le Leu et al., 2010). In addition, similar ﬁndings for protec-
tive effects of prebiotics on colonic cell proliferation have been ob-
served in rats fed fermentable substrates as inulin, FOS and
resistant starch (Femia et al., 2002; Le Leu et al., 2010). Thus, in-
creased SCFA concentrations resulting from fermentation of great
content of FOS contained in the yacon root could contribute to
the beneﬁcial effects on cell proliferation rather than apoptosis.
Several rodent studies have shown that prebiotics (i.e., fructo-
oligossacharides or frutans) probiotics and their combination syn-
biotics can provide protective effects against early biomarkers and
tumor development in the colon of carcinogen-treated rats (Reddy
et al., 1997; Reddy, 1998; Pool-Zobel et al., 2002; Pool-Zobel and
Sauer, 2007; Sivieri et al., 2008). Importantly, prebiotics and probi-
otics can survive and transit through the human and rodent gastro-
intestinal tract (Femia et al., 2002; Roberfroid et al., 2010; Yan and
Polk, 2010.) Yacon root saccharides, particularly b-(2? 1) fructool-
igosaccharides appear to be a good candidate as a prebiotic supple-ment (Valentová et al., 2006). In addition, it has been shown that
Lactobacillus acidophilus NRRL-1910, Lactobacillus plantarum NRRL
B-4496, and Biﬁdobacterium biﬁdum ATCC 15696 (Pedreschi et al.,
2003) and Lactobacillus casei Shirota were able to ferment yacon
FOS under anaerobic conditions (Buriti and Saad, 2007). In general,
synbiotic treatment is more beneﬁcial for reducing colon carcino-
genesis than treatment with probiotics or prebiotics (Gallaher
and Khil, 1999; Femia et al., 2002; Klinder et al., 2004). In the pres-
ent study, the greatest decrease in the number of and multiplicity
N.A. de Moura et al. / Food and Chemical Toxicology 50 (2012) 2902–2910 2909of aberrant crypt foci (ACF) and in the number of invasive and non-
invasive adenocarcinomas (multiplicity) was observed in the group
fed synbiotic formulation. This mild additive effect against colon
carcinogenesis could be attributed to the probiotic (Lactobacillus
casei) effect since various studies have suggested several health-
promoting mechanisms by which probiotics exert beneﬁcial effects
in human and laboratory animals (Fotiadis et al., 2008; Yan and
Polk, 2010; Wallace and Mackay, 2011).
A signiﬁcant reduction in the incidence of colon tumors
showing lowest altered b-catenin expression (i.e., loss or reduced
b-catenin protein at the cell-to-cell borders but an over-expression
in the cytoplasm and nucleus) was observed in the groups fed 1.0%
yacon or the synbiotic formulation. Since b-catenin is an important
Wnt signaling pathway activator, its level in the non-altered tissue
is adequately regulated by GSK-3b complex that targets its rapid
degradation in the cytoplasm to prevent translocation of b-catenin
into the nucleus and transcription of target genes, including genes
related to cell proliferation (Karim et al., 2004). In fact, c-myc and
cyclin D1 genes have been identiﬁed as targets of the b-catenin/
APC signaling (Karim et al., 2004). Thus, a potential role of dietary
yacon on the reduction of aberrant b-catenin expression could be
associated to a lower cell proliferation in colon tumors, indicating
that yacon could have a beneﬁcial effect on tumor progression
involving b-catenin/Wnt signaling pathway (Tarapore et al., 2012).
In conclusion, the ﬁndings this present investigation suggest
that yacon root intake may have potential as a chemopreventive
agent against colon carcinogenesis. The underlying mechanisms
of chemoprevention of colon carcinogenesis by yacon root still
must be investigated.Conﬂict of Interest
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